Journal
NATURE CHEMICAL BIOLOGY
Volume 3, Issue 6, Pages 323-324Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nchembio884
Keywords
-
Categories
Ask authors/readers for more resources
The diarylquinoline R207910 (TMC207) is a promising candidate in clinical development for the treatment of tuberculosis. Though R207910-resistant mycobacteria bear mutations in ATP synthase, the compound's precise target is not known. Here we establish by genetic, biochemical and binding assays that the oligomeric subunit c (AtpE) of ATP synthase is the target of R207910. Thus targeting energy metabolism is a new, promising approach for antibacterial drug discovery.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available